TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Otsuka Holdings Co ( (JP:4578) ) has shared an announcement.
Otsuka Holdings has received accelerated FDA approval for VOYXACT, a novel treatment for reducing proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This approval, based on significant results from a Phase 3 study, marks a significant advancement in IgAN treatment, offering a new therapeutic option with a unique mechanism of action that targets the APRIL pathway, potentially impacting the company’s market position and providing hope for patients with this chronic kidney disease.
The most recent analyst rating on (JP:4578) stock is a Buy with a Yen9950.00 price target. To see the full list of analyst forecasts on Otsuka Holdings Co stock, see the JP:4578 Stock Forecast page.
More about Otsuka Holdings Co
Otsuka Holdings Co., Ltd. operates in the pharmaceutical industry, focusing on innovative healthcare solutions. The company is known for its development and commercialization of pharmaceuticals, nutraceuticals, and medical devices, with a market focus on addressing unmet medical needs.
Average Trading Volume: 1,122,301
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen4519.6B
Learn more about 4578 stock on TipRanks’ Stock Analysis page.